Olivier Kitten
Founder & Chief Executive Officer Affilogic
Olivier is founder and CEO of Affilogic, a biotech company specialized in the development of alternative non-antibody ligands. Olivier was trained as an engineer, then as a researcher in gene transfer. Before creating the company, he held various positions in the pharmaceutical industry (Rhone-Poulenc Rorer, then Aventis Pharma Gencell in gene therapy), as laboratory head in a genetic testing biotech start-up, and as a cluster manager in the Nantes area (Atlanpole Biotherapies). Olivier now leads Affilogic and strategic alliances and programmes towards clinical applications of proprietary Nanofitins©.
Seminars
Thursday 4th February 2027
Pioneering Intranasal Delivery of Novel Biologics to Unlock New Therapeutic Opportunities
11:30 am
- Explore how next-generation biologic modalities can overcome traditional delivery barriers to enable effective intranasal administration while maintaining therapeutic activity
- Understand how intranasal biologics can leverage local mucosal immunity to provide differentiated therapeutic benefits across infectious disease and other emerging applications
- Learn from the development of novel biologic platforms and the scientific, translational, and regulatory considerations required to progress these therapies toward clinical success
